DVAX: Dynavax Technologies Market Cap to Revenue Ratio

Symbol and logo of brand Dynavax Pharma (DVAX)

Dynavax Technologies (DVAX) enjoys high physician confidence following the success of its hepatitis B vaccine. The price-to-sales ratio reflects the current market valuation, with the metric standing at 5.50. The business is protected by the mandatory nature of immunization, which ensures stability. However, reliance on a single flagship product and sector pressure create certain risks for growth.

DVAX Dynavax Technologies Corp Price-to-Revenue Ratio (07/04/2022 - 02/21/2026)

Dynavax Corp (DVAX) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart Dynavax Technologies Corporation|DVAX - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Dynavax Corp|DVAX - Real Price to Acquire Entire Company
- business book valuation details:
Net Asset Value per Share Dynavax|DVAX - Company Book Value|Capitalization to Book Value Ratio dynavax.com|DVAX - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Dynavax Technologies|DVAX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Dynavax Pharma|DVAX - Company Aggregate Debts|Debts to Book Capitalization Dynavax Corp|DVAX - Company Long-Term Liabilities|Company Short-Term Indebtedness Dynavax|Intermediate Coverage Ratio dynavax.com
- earnings and multiples data:
DVAX - Net Income|Future Net Profit Dynavax Technologies|DVAX - P/E Multiple|Projected Price to Earnings Ratio Dynavax|DVAX - PEG Multiple|Enterprise Value to EBITDA Ratio Dynavax Corp|DVAX - Operating profit EBITDA|Earnings per share for the trailing year Dynavax|DVAX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months dynavax.com|DVAX - Earnings per share growth in current year|Expected net earnings per share growth next year Dynavax Technologies
- total revenue and sales volume data:
DVAX - Company Revenue|Company Projected Revenue Dynavax Corp|DVAX - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio Dynavax Corp
General company analysis:DVAX dynavax.com
Signature product of Dynavax Pharma

When selecting defensive assets, investors seek a combination of stable cash flow and fair market value. For Dynavax Technologies (DVAX), scaling Heplisav-B vaccine sales creates operating leverage, making the market cap-to-revenue ratio a key indicator for assessing technology monetization efficiency and the extent of the premium paid for future earnings growth relative to current operating sales.

Who Dynavax Technologies competes with

ARWR (arrowheadpharma.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple MIRM (Mirum)|ABUS: Market Cap to Revenue Ratio|IVA: Market Cap to Revenue|Price to Sales Gyre Therapeutics Corp.|Assembly Biosciences (ASMB) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio GALT|GNFT (Genfit SA) - P/S Multiple|P/S Multiple DURECT Corp.|Market Cap to Revenue ALGS (Aligos Therapeutics)|Price-to-Revenue Ratio BIVI (biovieinc.com)|P/S Multiple GLMD (Galmed Pharmaceuticals Ltd.)|P/S Multiple endrainc.com NDRA|HEPA: Market Cap to Revenue